DONATE

New advances in the fight against the most common form of lung cancer

From left to right, Fernando Martín and Joan Montero at the Faculty of Medicine and Health Sciences. / Credit: University of Barcelona

A study led by the University of Barcelona in collaboraiton with the Institute for Bioengineering of Catalonia reveals that the functional assay dynamic BH3 profiling (DBP) can predict whether specific treatments will be effective in non-small cell lung cancer patients. The technique helps determine which therapy will be most effective by testing it directly on living cells, improving personalised therapies.

Researchers design a microfluidics device to predict cancer therapy response

One of the great challenges in the fight against cancer is to design new technologies for a personalized treatment for each patient. Depending on the molecular characteristics —DNA mutations for instance— of each tumour, precision medicine aims to make it easier for cancer patients, both adult and paediatric, to receive a personalized treatment that is appropriate to their pathology. But is it possible to know whether or not a patient can benefit from a treatment before starting therapy?

Advance in research against childhood cancer in the #WorldResearchCancerDay

IBEC researchers appear in different media for the recent study senior-authored by Joan Montero and first-authored by Albert Manzano, Senior Researcher and PhD student in IBEC’s Nanobioengineering group in which they have used a state-of-the-art analysis technique to evaluate new drug combinations to successfully treat acute lymphoblastic leukemia.

A new method to find the best treatment for pediatric cancer

A study led by researchers from the Nanobioengineering Group at IBEC, in collaboration with other research centers and hospitals in Barcelona, ​​uses a predictive biomarker to anticipate the success of drugs against rhabdomyosarcoma, which represents around 5 percent of childhood tumors . This advance can help in predicting treatment efficiency thus, avoiding tumor resistance and decreasing undesired secondary effects.

New method could help to find the best treatment for a pediatric cancer

A study led by IBEC researchers from the Nanobioengineering group, uses a functional predictive biomarker to anticipate the effect of treatments against rhabdomyosarcoma, the most common soft-tissue cancer affecting childhood and adolescence.

This advance can help in predicting treatment efficiency thus, avoiding tumor resistance and decreasing undesired secondary effects.